Literature DB >> 19120547

Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management.

J W Y Yau1, P Lee, T Y Wong, J Best, A Jenkins.   

Abstract

Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy and is a common cause of visual morbidity and blindness in the elderly. A large proportion of patients with RVO have a history of cardiovascular disease, hypertension, diabetes mellitus or open-angle glaucoma. Although RVO is sometimes associated with thrombophilias and coagulation abnormalities, the role of coagulation factors in the development of RVO remains unclear. This review did not find strong evidence to support an extensive work-up for thrombophilic and coagulation diseases for the vast majority of patients. However, when tests for common cardiovascular risk factors for RVO are negative, evaluation for potential coagulation disorders may be indicated, particularly in young patients and in patients with bilateral RVO, a history of previous thromboses or a family history of thrombosis.

Entities:  

Mesh:

Year:  2008        PMID: 19120547     DOI: 10.1111/j.1445-5994.2008.01720.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  51 in total

1.  Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis.

Authors:  Yan Sun; Yi Qu
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

2.  [Acute, bilateral visual loss in a patient with IgA glomerulonephritis].

Authors:  J Ehrhardt; F Gelisken
Journal:  Ophthalmologe       Date:  2018-03       Impact factor: 1.059

3.  Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria.

Authors:  Marc Sorigue; Jordi Juncà; Elisa Orna; Nevena Romanic; Edurne Sarrate; Jordi Castellvi; Montse Soler; Ines Rodríguez-Hernandez; Evarist Feliu; Susana Ruiz
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

4.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.

Authors:  Irini Chatziralli; George Theodossiadis; Stamatina A Kabanarou; Efstratios Parikakis; Tina Xirou; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-15       Impact factor: 3.117

Review 5.  [Cardiovascular and hemostaseological view of retinal vascular occlusions].

Authors:  H Seidel; E Stegemann; C Heiss
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

6.  Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Authors:  Irini Chatziralli; George Theodossiadis; Marilita M Moschos; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-18       Impact factor: 3.117

7.  Nanophthalmos and hemiretinal vein occlusion: A case report.

Authors:  Ahmad A Albar; Sawsan R Nowilaty; Nicola G Ghazi
Journal:  Saudi J Ophthalmol       Date:  2014-11-27

8.  Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment.

Authors:  Marina Turello; Samantha Pasca; Roberto Daminato; Patrizia Dello Russo; Roberta Giacomello; Ugo Venturelli; Giovanni Barillari
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 9.  Nanoengineering of therapeutics for retinal vascular disease.

Authors:  Nivriti Gahlaut; Sandra Suarez; Md Imam Uddin; Andrew Y Gordon; Stephanie M Evans; Ashwath Jayagopal
Journal:  Eur J Pharm Biopharm       Date:  2015-05-28       Impact factor: 5.571

10.  Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion.

Authors:  E Moisseiev; M Goldstein; M Waisbourd; A Barak; A Loewenstein
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.